JAPANESE researchers have begun clinical trials for a treatment for familial Alzheimer’s Disease.
Researchers from Niigata University and the University of Tokyo announced that they have started an international clinical trial for a familial Alzheimer’s Disease treatment.
The testing will determine the effectiveness and safety of administering a combination of the Alzheimer’s drug Lecanemab and a new drug under development.
According to the researchers, the clinical trial is underway in 16 countries.
In a statement, Niigata University Professor Takeshi Ikeuchi said,
“If the treatment proves effective in the clinical trial, it is expected to lead to the development of a treatment for sporadic Alzheimer’s disease, which affects a large number of patients.”
It can be noted that familial Alzheimer’s Disease is usually reported in people in their 30s to 50s with such patients making up less than 1 percent of all Alzheimer’s patients.
